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Purpose: The outflow facility for aqueous humor across the trabecular meshwork (TM) is enhanced by agents that oppose
the actomyosin contraction of its resident cells. Phosphorylation of MYPT1 (myosin light chain [MLC] phosphatase
complex of Type 1) at Thr853 and Thr696 inhibits dephosphorylation of MLC, leading to an increase in actomyosin
contraction. In this study, we examined the effects of Rho kinase (ROCK) inhibitors on the relative dephosphorylation of
the two sites of MYPT1 using human TM cells (GTM3).
Methods: Dephosphorylation of MYPT1 at Thr853 and Thr696 was determined by western blot analysis following
exposure to selective inhibitors of ROCK, namely Y-27632 and Y-39983. Consequent dephosphorylation of MLC and
decreases  in  actomyosin  contraction  were  assessed  by  western  blot  analysis  and  collagen  gel  contraction  assay,
respectively. Changes in the cell-matrix adhesion were measured in real time by electric cell-substrate impedance sensing
and also assessed by staining for paxillin, vinculin, and focal adhesion kinase (FAK).
Results: Both ROCK inhibitors produced a concentration-dependent dephosphorylation at Thr853 and Thr696 of MYPT1
in adherent GTM3 cells. IC50 values for Y-39983 were 15 nM and 177 nM for dephosphorylation at Thr853 and Thr696,
respectively. Corresponding values for Y-27632 were 658 nM and 2270 nM. Analysis of the same samples showed a
decrease in MLC phosphorylation with IC50 values of 14 nM and 1065 nM for Y-39983 and Y-27632, respectively.
Consistent with these changes, both inhibitors opposed contraction of collagen gels induced by TM cells. Exposure of
cells to the inhibitors led to a decrease in the electrical cell-substrate resistance, with the effect of Y-39983 being more
pronounced than Y-27632. Treatment with these ROCK inhibitors also showed a loss of stress fibers and a concomitant
decrease in tyrosine phosphorylation of paxillin and FAK.
Conclusions: Y-39983 and Y-27632 oppose ROCK-dependent phosphorylation of MYPT1 predominantly at Thr853 with
a corresponding decrease in MLC phosphorylation. A relatively low effect of both ROCK inhibitors at Thr696 suggests
a role for other Ser/Thr kinases at this site. Y-39983 was several-fold more potent when compared with Y-27632 at
inhibiting the phosphorylation of MYPT1 at either Thr853 or Thr696 commensurate with its greater potency at inhibiting
the activity of human ROCK-I and ROCK-II enzymes.
The  outflow  of  aqueous  humor  across  the  trabecular
meshwork  (TM)  is  regulated  by,  among  other  factors,
actomyosin contraction of the resident TM cells and altered
extracellular matrix (ECM) [1-3]. Ex vivo perfusion studies
have demonstrated that agents that increase the actomyosin
contraction of TM cells decrease aqueous humor outflow and
vice versa [4-6]. These observations led to the hypothesis that
the contraction of TM cells regulates the outflow facility,
possibly through the reorganization of the TM through altered
cell-ECM interactions.
Actomyosin  contraction  is  dependent  on  the
phosphorylation of the regulatory light chain of myosin II
(also called the myosin light chain or MLC; 20 kDa). MLC is
phosphorylated at its Ser19 and/or Thr18 residues by MLC
kinase  (MLCK),  which  is  a  (Ca2+-calmodulin)-dependent
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kinase  [7].  Accordingly,  G  protein-coupled  receptors
(GPCRs)  that  mobilize  intracellular-free  Ca2+  ([Ca2+]i)
activate MLCK and induce MLC phosphorylation. However,
sustained contraction is dependent on the activity of MLC
phosphatase (MLCP) [8-10]. Investigations in the last decade,
notably of smooth muscle cells, have unraveled the molecular
aspects related to the regulation of MLCP [11,12]. It is now
known that MLCP is a complex of three subunits: a regulatory/
myosin  binding  subunit  (MYPT1),  a  catalytic  subunit
(PP1cδ),  and  M20  [12].  The  MLCP  activity  is  regulated
through MYPT1 phosphorylation by many kinases, including
integrin-linked kinase (ILK), protein kinase C (PKC), ZIP
kinase,  and  Rho-associated  coiled-coil-containing  protein
kinase (ROCK) [13]. In a variety of cell types, ROCK is
known  to  inhibit  the  phosphatase  activity  of  MLCP  by
phosphorylating  MYPT1  at  Thr696  and  Thr853  [14,15].
However, differences in the correlation between the site of
MYPT1  phosphorylation  and  the  extent  of  MLC
phosphorylation  and/or  force  generation  have  also  been
documented [16,17]. Given the important role of ROCK in the
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C. Ramachandran,1 R.V. Patil,2 K. Combrink,2 N.A. Sharif,2 S.P. Srinivas1regulation  of  actomyosin  contraction,  there  is  significant
interest in employing its inhibitors to facilitate outflow across
the TM [18,19], and thus ROCK inhibitors are of special
interest as potential ocular hypotensive agents.
In this study, we investigated the molecular targets of
ROCK on actomyosin contraction in TM cells. Specifically,
we  focused  on  establishing  the  relative  significance  of
phosphorylation of MYPT1 by ROCK at Thr696 as compared
with Thr853. Our approach involved challenging a human TM
cell line with two relatively selective inhibitors of ROCK,
followed by assaying the degree of dephosphorylation of the
two inhibitory sites. These inhibitors, namely, Y-27632 and
Y-39983, are known to increase the outflow facility across
TM  [19-21].  We  confirmed  the  impact  of  the
dephosphorylation  downstream  in  terms  of  MLC
phosphorylation,  actomyosin  contraction,  and  cell-matrix
adhesion. Our results show that the predominant inhibitory
phosphorylation  site  of  MYPT1  regulated  by  ROCK  is
Thr853. Inhibition of phosphorylation at this site correlates
with  a  decrease  in  MLC  phosphorylation  as  well  as  in
actomyosin contraction. As a consequence of the latter, the
inhibition  of  ROCK  also  results  in  a  loss  of  cell-ECM
adhesion, which may increase the aqueous humor outflow
facility  deemed  useful  for  lowering  intraocular  pressure
(IOP).
METHODS
Drugs and chemicals: MYPT1, phospho-MYPT1 (Thr853),
phospho-MLC  (Thr18  and  Ser19),  phospho-paxillin
(Tyr118), and FAK (Tyr397) antibodies were obtained from
Cell Signaling Technology (Danvers, MA). Phospho-MYPT1
(Thr696) antibody was bought from Millipore (Temecula,
CA).  Anti-paxillin  antibody  was  purchased  from  BD
biosciences (San Jose, CA), and anti-vinculin antibody, along
with blebbistatin and Y-27632, from Sigma (St. Louis, MO).
Y-39983  was  synthesized  at  Alcon  Research,  Ltd.  (Fort
Worth,  TX).  Texas-Red  conjugated  phalloidin,  Alexa-488
conjugated goat-anti mouse, and anti-rabbit antibodies were
purchased  from  Molecular  Probes  (Eugene,  OR).  Gold
electrodes (8W10E+) for measuring electrical cell-substrate
resistance (ECSR) were purchased from Applied Biophysics,
Inc. (Troy, NY), and the SuperScript III Cells Direct cDNA
Synthesis Kit was from Invitrogen (Grand Island, NY).
Cell  culture:  Cell  cultures  of  an  immortalized  human
glaucomatous trabecular meshwork (GTM3) cell line were
grown at 37 °C in 5% CO2 in Dulbecco’s Minimum Essential
Medium (DMEM + Glutamax) supplemented with 10% fetal
bovine serum and 10 μg/ml of gentamicin (Invitrogen, Grand
Island,  NY)  as  previously  described  [22].  Upon  reaching
confluence, cells were divided using 0.05% trypsin. Cells of
passages 13 to 20 were used in our experiments.
Western blot analysis of MYPT1 and MLC phosphorylation:
Following treatment with the desired drugs/agents, cells were
rinsed in PBS and solubilized in 300 µl of 2× Laemmli sample
buffer. The lysate was sonicated briefly and boiled for 5 min.
Equal amounts of protein (30 μg) were loaded in 8% or 12%
SDS–PAGE gels. Following electrophoresis, proteins were
transferred to a nitrocellulose membrane (Biorad, Hercules,
CA), blocked with 5% fat-free milk for 1 h, and incubated with
specific  phospho-MYPT1  or  phospho-MLC  antibodies
overnight.  The  membranes  were  next  incubated  with  the
appropriate  secondary  antibodies  for  1  h.  The  blots  were
finally  washed  and  developed  using  an  enhanced
chemiluminescence kit (Pierce, Rockford, IL) according to
the manufacturer’s instructions.
Immunofluorescence: Cells were first treated for the indicated
time  period  in  the  serum-rich  medium  described  earlier.
Following a brief rinse with PBS, cells were fixed with 4%
paraformaldehyde for 10 min and then permeabilized with
0.1% Triton-X for 10 min. For phosphorylated MLC staining,
cells were blocked with 10% goat serum + 3% BSA, and, for
vinculin and paxillin staining, the cells were blocked with
10% FBS for 1 h. Cells were incubated in primary antibody
overnight, followed by secondary antibody incubation for 1 h.
Double staining for actin was performed by incubating cells
in Texas-red conjugated phalloidin for 20 min. After extensive
washing, coverslips were mounted using ProLong AntiFade
(Molecular Probes, Eugene, OR). Images were acquired using
a Leica SP5 (Leica Microsystems, Bannockburn, IL) confocal
microscope. After similar treatments, DIC images of cells
fixed on coverslips were also obtained using a Nikon E800
(Nikon Instruments, Melville, NY) microscope.
Collagen gel contraction assay: A collagen gel contraction
assay was performed as previously described [23,24]. The
wells of 24-well culture plates were coated with 1% BSA at
37 °C for 1 h. Glaucomatous trabecular meshwork cells were
trypsinized and resuspended in culture medium at a density of
1×107 cells/ml. Rat-tail collagen Type I (BD Biosciences, San
Jose, CA), 10× DMEM (Sigma, St. Louis, MO), reconstitution
buffer (pH 7.3), TM cell suspension, and distilled water were
mixed on ice to obtain a final concentration of 1.9 mg/ml of
collagen  and  a  final  cell  density  of  2×105  cells/ml.  The
resultant mixture (0.5 ml) was added to each well of the BSA-
coated  culture  clusters,  and  collagen  gel  formation  was
induced by incubation at 37 °C for 90 min. Serum-rich or
serum-free DMEM (0.5 ml), without or with the drugs, was
then added on top of the gels. After 1 h, the gels were freed
from the walls of the culture wells. They were subsequently
imaged every 24 h for 2 days. The area was calculated using
NIH ImageJ software.
Reverse transcription polymerase chain reaction: Total RNA
was isolated using Trizol reagent (GIBCO BRL, Grand Island,
NY)  and  quantified  by  measuring  absorption  at  260  nm.
Genomic DNA contamination was removed by treating the
extraction with DNase I. First-strand cDNA synthesis and
PCR  amplification  of  cDNA  was  performed  using  the
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Carlsbad,  CA).  Reverse  transcription  polymerase  chain
reaction (RT–PCR) products were run on a 2% agarose gel
and  visualized  by  ethidium  bromide  staining  along  with
100 bp markers (Amersham Biosciences, Piscataway, NJ).
The primer sequences and expected product sizes are given in
Table 1. The products were confirmed with corresponding
negative controls performed for all the primer pairs employed.
TABLE 1. PRIMER SEQUENCES.
Gene ID Primer sequence Ta Size (bp) References
Myosin IIA Sense: GAAGGTCATCCAGTATCTGGCG 52 355 [46]
  Antisense: ACAGGAAGCGGTATTTGTTGTACG
Myosin IIB Sense: AGAAGGGCATGTTTCGTACCG 52 236 [46]
  Antisense:TGAATTCCTGGAAAACTATTCGGTTAG
Myosin IIC Sense: AAGCCATTGTGGAGATGTACCG 52 386 [46]
  Antisense: GGTAGGTCTCAATGTTGGCGC
MYPT1 Sense: CCGTATTGAATCTCTGGAACAAG 55 308 [42]
  Antisense: TTGCAGGAGACTCATCTTTTCTC
MYPT2 Sense: GAAGGTGAAGATGAAGCTTCTGA 60 240 [42]
  Antisense: AGTTTTTCTCAGTCCCAATCTCC
ROCK1 Sense: CTCCGAGACACTGTAGCACCAGTT 63 328 [42]
  Antisense: TTTGAGGTTCTGCACTTCTGCTCC
ROCK2 Sense: TTAAGGAAAACCCAGGCAGAAGT 60 375 [42]
  Antisense: TTCTTCTTGTTCTAGGCTCTGCTG
EC-MLCK Sense: AGGTGCTTCAGAATGAGGACGTGT 56 130 [43]
  Antisense: TGTAGCATCAGTGACACCTGGCAA
SM-MLCK Sense: TGAGCTGTTCGAGCGCATCATT 52 167 [10]
  Antisense:TGGTGCCTGTCTTGTTGACACA
Figure  1.  Expression  of  myosin  II,
MYPT, ROCK, and MLCK isoforms in
GTM3  cells.  Expression  pattern  of
genes in cultured cells was determined
using total RNA- and sequence-specific
oligonucleotide primers. A: These cells
express  two  isoforms  of  myosin  II,
namely, MYH9 and MYH10. The other
isoform, MYH14, was undetectable. In
addition,  the  expression  of  both
isoforms of MYPT, ROCK, and MLCK
(B,  C,  D)  was  confirmed.
Abbreviations:  MYH9:  myosin  IIA;
MYH10: myosin IIB; MYH14: myosin
IIC; ROCK: Rho kinase; MYPT: myosin
phosphatase; MLCK: myosin light chain
kinase.
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1879Electrical  cell-substrate  impedance  sensing:  Cells  were
seeded on gold electrode-plated culture plates (8W10E+) and
placed in an incubator at 37 °C with humidified air and 5%
CO2. The attachment and spreading of the cells on electrodes
was  monitored  continuously  at  4  kHz  until  the  observed
electrical resistance reached a plateau and stabilized. This
usually occurred within 20–24 h after inoculation. Impedance
to current flow was measured at different frequencies (25 Hz
to 60 kHz) periodically before and after inoculation. After
reaching the steady-state of electric-cell substrate resistance,
cells were exposed to the ROCK inhibitors, and the impedance
was  assessed  at  different  frequencies  every  30  min.  The
change in the measured resistance normalized to that of the
bare electrode was taken as a measure of cell-matrix adhesion
as discussed further below.
Data analysis: A one-way ANOVA was used to compare
mean values for different treatments with Bonferroni’s post-
test analysis (Prism 5.0 for Windows; GraphPad Software,
Inc., San Diego, CA). Results are expressed as mean±SEM.
For  analysis  of  ECIS  (electrical  cell-substrate  impedance
sensing) data, normalized numerical values from individual
experiments were pooled and expressed as mean±SEM. A
p  value  of  less  than  0.05  was  considered  statistically
significant.  “n”  denotes  the  number  of  independent
experiments performed. The IC50 values were determined by
fitting  the  normalized  response  to  the  curve  Y=100/
(1+10^((X-LogIC50)))  where  Y  denotes  the  normalized
response and X is the log[concentration] of the drug. The
calculations assume that log [drug] versus response follow a
sigmoidal shape and were performed with Prism 5.0. The
reported values of R indicate goodness of fit.
RESULTS
Expression of myosin II, ROCK, MLCK, and MYPT isoforms:
The GTM cell line was developed from a transformed strain
of  TM  cells  obtained  from  a  glaucomatous  donor  [22].
Various pharmacological and morphological aspects of the
cell line and comparison with normal human TM cells have
been documented [22]. There were significant similarities
between  the  two,  as  shown  by  the  expression  of  specific
cytoskeletal proteins, including tubulin, vimentin, α-SMA,
and those associated with the ECM [22]. To facilitate our
study on actomyosin contraction, we examined the expression
of different isoforms of important actin cytoskeletal proteins
at the mRNA level. As shown in Figure 1A, two isoforms of
myosin  II,  namely,  myosin  IIA  (MYH9)  and  myosin  IIB
(MYH10), are expressed in the GTM cells. We failed to detect
the expression of myosin IIC (MYH14). The known isoforms
of MYPT (MYPT1 and MYPT2) and ROCK (ROCK-I and
ROCK-II) were also expressed, along with the two MLCK
splice variants (i.e., EC- and SM-MLCK; Figure 1B-D).
Effect of ROCK inhibitors on MYPT1: Consistent with the
mRNA expression, MYPT1 expression in GTM cells was also
noted at the protein level (Figure 2A). The two bands indicated
by arrows in Figure 2A possibly correspond to the splice
variants of 133 kDa and 130 kDa (shown by arrows in Figure
2A) [25]. Furthermore, as shown in Figure 2A, exposure to
5  μM  of  Y-27632  or  Y-39983  led  to  the  complete
dephosphorylation  of  MYPT1  at  Thr853.  However,  in
Figure 2. Effect of ROCK inhibitors on
the  phosphorylation  of  MYPT1  and
MLC. Cells were treated with 5 μM of
the specific ROCK inhibitors, Y-27632
and Y-39983, for 1 h in a serum-rich
medium.  A:  Treatment  with  ROCK
inhibitors  completely  opposed  the
phosphorylation of MYPT1 at Thr853.
There was a concomitant decrease in the
phosphorylation of MLC. However, the
phosphorylation of MYPT1 at Thr696
was  only  slightly  reduced  in  the
presence  of  Y-27632  compared  to
Y-39983. B: In the presence of ROCK
inhibitors,  there  was  a  loss  in  stress
fibers,  and  the  staining  for  MLC
appeared diffuse.
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1880contrast  to  Y-39983,  Y-27632  induced  a  comparatively
smaller  reduction  in  MYPT1  phosphorylation  at  Thr696
(Figure 2A; middle lane). We next characterized the impact
of the ROCK inhibitors on the dephosphorylation of MLC as
a direct measure of the phosphatase activity of MLCP. In
agreement with the impact on MYPT1 phosphorylation sites,
both  the  ROCK  inhibitors  reduced  MLC  phosphorylation
(diphospho  form;  denoted  as  ppMLC;  Figure  2B).
Immunocytochemistry data also showed that the intensity of
ppMLC staining along F-actin was reduced. In addition, there
was a loss of stress fibers in response to Y-27632 and Y-39983
(Figure 2B; middle and bottom rows).
To  characterize  further  the  differential  sensitivity  of
MYPT1 phosphorylation sites to the ROCK inhibitors, we
determined their IC50 values (i.e., concentration required to
reduce phosphorylation of MYPT1 by 50%). Figure 3A is a
typical concentration response of the dephosphorylation of
MYPT1 and ppMLC to Y-27632 (10 nM to 5 μM). The IC50
for dephosphorylation at Thr696 for Y-27632 was 2270 nM
(Figure 3B) in contrast to ~660 nM for dephosphorylation at
Thr853  (Figure  3C).  The  latter  was  close  to  the  IC50  for
dephosphorylation of MLC (1065 nM; Figure 3D). Similar
experimental results with Y-39983 are shown in Figure 4.
Unlike Y-27632, Y-39983 showed an IC50 of ~200 nM for
dephosphorylation at Thr696 (Figure 4B) and only 15 nM for
dephosphorylation  at  Thr853  (Figure  4C).  The  IC50  for
dephosphorylation of MLC was 14 nM (Figure 4D), which
was close to the IC50 for Thr853 (Figure 4D). Taken together,
these results show that Thr853 is the preferred site for the
ROCK-mediated inhibition of MLCP. In addition, the data
also indicates that Y-39983 is more potent than Y-27632 at
inhibiting the influence of ROCK on MLCP activity.
Effect of ROCK inhibitors on actomyosin contraction: To
evaluate  further  the  effects  of  the  ROCK  inhibitors  on
MYPT1, we examined their potential downstream effects. As
a  measure  of  the  direct  effect  of  MYPT1,  we  performed
collagen  gel-contraction  assays  to  assess  actomyosin
contraction, which is dependent on MLC phosphorylation.
For this purpose, we first formed collagen gels showing an
average area of 140 mm2 1 h after polymerization. In the
presence of 10% serum, GTM cells at a density of 2×105 cells/
ml led to a reproducible reduction in the area of the gels to
~60 mm2 in 48 h (Figure 5A,B). In the absence of serum, gels
contracted 18±0.5% less compared with the presence of serum
(n=4). When the cells were treated with Y-39983 for 48 h,
there was an increase in the gel area by 86±5% (1 μM; n=3)
and 105+1.2% (5 μM; n=7) compared with the control (Figure
5B). This significant relaxation in the presence of Y-39983
was much more than that obtained in response to Y-27632.
Compared with the two ROCK inhibitors, a selective myosin
II ATPase inhibitor, blebbistatin (10 μM), induced relaxation
by  102±1.3%  (n=5).  Interestingly,  this  was  similar  to  the
efficacy of Y-39983 at 5 μM (Figure 5A,B).
Effect of ROCK inhibitors on cell-matrix adhesion: Changes
in electrical cell substrate resistance: We examined the cell-
matrix adhesion as a second measure of the impact of ROCK
inhibitors  on  MYPT1.  It  is  well  known  that  actomyosin
contraction  and  cell-matrix  adhesion  possess  a  reciprocal
Figure  3.  Concentration  response  to
Y-27632. Confluent cells were treated
with Y-27632 (10 nM to 5 μM) for 1 h
in  serum-rich  medium.  A:
Representative data of the dose response
of MYPT1 and MLC phosphorylation to
Y-27632 (50 nM to 1 μM). There was
only  a  marginal  decrease  in  the
phosphorylation of MYPT1 at Thr696,
even at a drug concentration of 5 μM.
B, C, and D: Densitometric analysis of
western blot data shown in panel A. The
IC50  of  MYPT1  phosphorylation  at
Thr696  (IC50=2270  nM;  B)  is  three
times that of Thr853 (IC50=658 nM; C).
The data obtained for phosphorylation
at  Thr696  were  less  repeatable  and
consistent (R2=0.39) compared with that
obtained  for  Thr853  and  MLC
(R2=~0.8). However, there is a better
correlation  between  MYPT1
dephosphorylation at Thr853 and MLC
dephosphorylation  (D)  with  near
complete  inhibition  of  both  at  a
concentration of 5 μM.
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1881relationship  through  their  linkage  via  integrins  [26].  We
directly  assessed  cell-matrix  adhesion  using  electric  cell-
substrate impedance sensing (ECIS; see Methods) and then
indirectly  characterized  it  in  terms  of  the  tyrosine
phosphorylation of key proteins found at the focal adhesion
sites.
ECIS involves the measurement of impedance to a small
AC current applied across cells grown to confluence on planar
gold  microelectrodes  [27,28].  The  measurement  is  non-
invasive, and off-the-shelf instruments such as ECISTM 1600R
(Applied Biophysics, Inc., Troy, NY) make use of a lock-in
amplifier to measure small changes in electrical impedance at
a high-temporal resolution. We have previously employed
ECIS to assess the integrity of the apical junctional complex
of the corneal endothelial monolayers [29-31]. For epithelial
monolayers, such as the corneal endothelium, the resistive
component  of  the  measured  impedance  implies  trans-
endothelial electrical resistance for current flow between the
cells when confluent on the electrode [29-32]. However, with
non-epithelial cells, such as fibroblasts, measured impedance
arises mainly out of resistance to current flow across the cell
substrate (i.e., cell-matrix adhesion) [33,34]. In this study, we
examined the dynamics of such cell-matrix resistance (i.e.,
resistive component of the measured impedance) with TM
cells.  After  seeding  GTM  cells  on  gold  electrodes,  the
measured resistance with AC current at 4 kHz showed a steep
peak in resistance, reaching ~1400 Ω within 3 h (Figure 6A).
This increase can be attributed to the attachment of cells to the
substrate  (gold  electrode),  which  leads  to  an  increased
resistance to current flow. Following this first phase, there is
a gradual increase in the resistance to ~1600 Ω, reaching a
steady-state at ~24 h (Figure 6A).
After the observed ECSR reached a steady-state, cells
were challenged with the ROCK inhibitors, and the time-
dependence of the ECSR was followed at several frequencies
(Figure 6B). These frequency scans were intended to identify
the  frequency  at  which  the  altered  ECSR  would  be  most
sensitive.  It  is  apparent  from  these  figures  that  the  most
sensitive frequency for TM cells is 7 kHz. Treatment with
5 μM of Y-27632 for 2 h led to a significant decrease in the
peak resistance compared with untreated cells (Figure 6B). y-
axis  represents  the  change  in  ECSR  normalized  to  the
resistance of the corresponding bare electrode. Although the
maximum decrease was attained after 1 h of treatment, the
reduction in ECSR remained constant for up to 2 h. Treatment
with Y-39983 at 1 μM led to a similar decrease in ECSR,
showing  a  large  decrease  by  30  min  at  the  same  peak
frequency and reaching a constant at 1 h. Unlike Y-27632, the
response to Y-39983 was rapid and more pronounced (Figure
6B).  Exposure  to  cytochalasin  D,  a  known  actin-
depolymerizing agent, or an integrin-binding RGD peptide
(cyclo-RGD peptide from Anaspec, Inc. [Fremont, CA], at
100 nM) also led to a substantial decrease in the resistance
(Figure 6C).
Effect  of  the  ROCK  inhibitors  on  cell-matrix  adhesion:
Changes  in  cell  shape  and  focal  adhesion:  Actomyosin
contraction  affects  cell  shape  and  cell-matrix  adhesion
through its impact on the stress fibers. The altered cell-matrix
adhesion manifests in part by tyrosine phosphorylation of
focal adhesion proteins such as FAK, vinculin, and paxillin.
Figure  4.  Concentration  response  to
Y-39983. Confluent cells were treated
with Y-39983 (3 nM to 5 μM) for 1 h in
serum-rich medium. A: A typical dose
response  of  MYPT1  and  MLC
phosphorylation  to  treatment  with
Y-39983 (50 nM to 1 μM). B, C, and
D:  Densitometric  analysis  of  western
blot data shown in panel A. B: There was
a  dose-dependent  decrease  in  the
phosphorylation of MYPT1 at Thr696
(IC50=177  nM).  C:  The  inhibition  of
MYPT1  phosphorylation  at  Thr853
assumes a sigmoid curve compared with
Thr696.  There  is  a  much  steeper
decrease  in  Thr853  phosphorylation
with  an  IC50  of  15  nM.  D:  The
dephosphorylation  of  MLC  followed
Thr853 closely with an IC50 of 14 nM.
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assembly  of  the  focal  adhesion  complexes  and  their
association with the actin cytoskeleton [35]. The changes in
cell shape in response to ROCK inhibitors are shown in the
DIC images in Figure 7. When treated with Y-27632 (5 μM;
Figure 7B) and Y-39983 (1 μM; Figure 7C) for 1 h, there was
an  apparent  shrinkage,  with  cells  assuming  a  stellate
appearance compared to control.
The disposition of the stress fibers with and without the
ROCK inhibitors is shown in Figure 7, along with changes in
tyrosine  phosphorylation  of  the  focal  adhesion  proteins
(Figure 8). In untreated cells, as shown in Figure 7D, stress
fibers are found along the cell periphery and across the cell
body (shown by arrows). We have also shown the staining for
focal adhesion protein paxillin in Figure 7G. Consistent with
the  strong  adhesion  in  untreated  cells,  there  was  intense
punctuate staining for the adhesion protein along the stress
fibers. When cells were treated with the ROCK inhibitors, a
loss in stress fibers at the periphery and across the cell body
was apparent (Figure 7E,F). In addition, staining for paxillin
became less prominent compared with control (Figure 7H,I).
All the above responses were also observed when cells were
treated with integrin-binding RGD peptide (data not shown).
Consistent with the immunofluorescence data, tyrosine
phosphorylation  of  FAK  and  paxillin  were  altered  in  the
presence of ROCK inhibitors (data for Y-27632 not shown).
The addition of 10% serum to cells led to an increase in
tyrosine phosphorylation of FAK (Tyr397; Figure 8A) and
paxillin (Tyr118; Figure 8B). The ROCK inhibitors opposed
this serum-induced increase in tyrosine phosphorylation of the
adhesion proteins (Figure 8A,B). Taken together, the data in
Figure  6,  Figure  7,  and  Figure  8  indicate  that  loss  in
actomyosin contraction results in altered cell morphology due
to weakening of primarily the cell-ECM adhesions.
DISCUSSION
In humans, more than 80% of aqueous humor exits the anterior
chamber via the TM route [36-38]. Therefore, outflow facility
across TM is the primary determinant of IOP. Apart from
pilocarpine,  there  are  no  drugs  that  elicit  significant  IOP
Figure 5. Effect of ROCK inhibitors on
collagen gel contraction. Cells grown in
collagen  gels  were  incubated  without
(control)  or  with  ROCK  inhibitors
Y-27632 (5 μM or 10 μM), and Y-39983
(1 μM or 5 μM) for 48 h. Changes in the
area of the gels were calculated using the
ImageJ program from NIH. The initial
area of the gels (measured before the
addition of drugs) was ~140 mm2. A:
The presence of serum contracted the
gels significantly. This serum-induced
contraction  was  opposed  by  both
Y-27632 and Y-39983, with the latter
having  a  more  significant  effect.
Blebbistatin (10 μM), a specific myosin
II ATPase inhibitor, was employed to
confirm that the observed changes in the
gel  area  resulted  from  increased
actomyosin contraction. B: A bar graph
of the results from several independent
experiments.  As  can  be  noted,  the
absence  of  serum  led  to  a  lesser
contraction  (by  18±0.5%)  of  the  gels
compared  to  serum  (~60  mm2)  after
48 h. The ROCK inhibitors significantly
opposed the decrease in the gel area. At
10  μM  Y-27632,  the  gel  area  had
increased by 50%, while, even at 1 μM,
Y-39983  opposed  actomyosin
contraction  more  effectively  (86±5%)
compared with the control. The gel area
obtained  with  10  μM  of  blebbistatin
(denoted as Bstat) was similar to that
obtained with 5 μM Y-39983. The data
are represented as mean±SEM.
Molecular Vision 2011; 17:1877-1890 <http://www.molvis.org/molvis/v17/a205> © 2011 Molecular Vision
1883reduction  by  enhancing  outflow  across  TM  without
significant  side  effects.  Prostaglandin  analogs,  the  most
efficacious ocular hypotensive drugs to date, mainly lower
IOP by increasing outflow via the uveoscleral pathway [39].
Clearly, there is a challenge to find novel pharmaceutical
agents to modulate the TM to elicit further reductions in IOP.
Recent studies have gathered significant evidence to suggest
that it is possible to manipulate the actin cytoskeleton of TM
cells to alter the aqueous outflow facility. As noted earlier,
drugs  that  enhance  actomyosin  contraction  are  known  to
increase resistance to outflow facility and vice versa [5,40,
41]. Although a mechanistic link between actin cytoskeleton
and outflow facility is not well understood, a dynamic ECM
involvement seems likely. To delineate this phenomenon, it
is imperative to establish the signaling underlying actomyosin
contraction in TM cells and its coupling to the ECM. In this
study,  we  set  out  to  distinguish  the  two  specific
phosphorylation sites (Thr853 and Thr696) on MYPT1 that
are thought to be central to actomyosin contraction via the
RhoA-Rho  kinase  axis.  Specifically,  we  investigated  the
differential  action  of  two  ROCK  inhibitors  on  the
phosphorylation  of  MYPT1  at  the  two  sites.  Both  the
inhibitors  have  been  reported  to  increase  outflow  facility
across the TM in ocular perfusion studies and in vivo in animal
models  and  to  lower  IOP  [19-21,42].  Our  major  findings
indicate that the effect of ROCK inhibitors is predominantly
at Thr853 of MYPT1 and that consequent loss of actomyosin
contraction  weakens  the  cell-matrix  adhesion  and  alters
cellular  morphology.  Thus,  our  results  suggest  a  distinct
molecular  target  to  assess  the  impact  of  potential  ROCK
inhibitors  or  other  mechanisms  of  RhoA-Rho  kinase  axis
antagonism on TM cells (summarized in Figure 9).
Characterization of GTM3 cells: In the context of our
specific  objectives  outlined  above,  we  performed  our
experiments with a TM cell line (i.e., GTM3 cells) developed
previously from a human donor with glaucoma [22]. As noted
earlier, these GTM3 cells are similar to normal human TM
cells  with  a  similar  expression  profile  of  key  structural
proteins and characteristic cell signaling responses to several
G-protein  coupled  receptor  (GPCR)  agonists  [22].  As  an
extension of the earlier experiments, we characterized GTM3
cells  by  determining  the  expression  profile  of  proteins
involved in the regulation of actomyosin contraction. As in
smooth muscle cell types, GTM cells were found to express
Figure  6.  Cell-substrate  impedance
sensing. A: The evolution of resistance
after  seeding  TM  cells.  Upon
inoculation, the resistance measured at
4 kHz increased within 3 h. This was
followed  by  a  gradual  increase  in
resistance (around 1600 ohms), which
reached a plateau around 24 h. B: The
impedance changes induced by ROCK
inhibitors. To measure the changes in
the  measured  resistance,  frequency
scans were taken every 30 min to obtain
resistance values across 23 frequencies
(23  Hz  to  60  kHz)  from  each  well.
Treatment of cells with 5 μM Y-27632
or 1 μM Y-39983, denoted by closed
squares and broken lines, respectively,
led  to  a  significant  decrease  in
resistance.  The  decrease  in  resistance
started at 30 min, reached a maximum at
1 h, and remained constant until 2 h after
treatment. C: Treatment of cells with
cytochalasin  D  (0.125  mg/ml;  closed
diamonds),  an  actin-depolymerizing
agent, led to a significant decrease in the
measured  resistance.  Similarly,
treatment  with  an  RGD-peptide
(100  nM;  a  specific  integrin  binding
peptide) led to a significant decrease in
resistance (dashed lines) compared with
the control (closed circles). Data shown
are expressed as mean±SEM of three
independent experiments.
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1884different  isoforms  of  the  myosin  II,  MLCK,MYPT,  and
ROCK genes. The expression of the short isoform of MLCK
was first reported in smooth muscle cells (hence, called SM-
MLCK),  while  the  longer  splice  variant  (EC-MLCK)  was
found  in  vascular  endothelial  cells  and  other  non-smooth
muscle  cell  types  (e.g.,  corneal  endothelium)  [43].  This
expression pattern is similar to that of bovine TM cells [44].
The expression of ROCK isoforms (ROCK-I and ROCK-II
isoforms) is not unique to GTM cells, as their expression has
been reported in the TM cells derived from bovine, monkey,
and human sources [20,42,45]. A recent study by Nakajima et
al.  [42]  showed  the  expression  of  MYPT1  and  MYPT2
isoforms in monkey and human TM, and hence the expression
in GTM cells, was also as expected. Expression of myosin II
isoforms MYH9 and MYH10, but not of MYH14, has been
previously reported in normal TM cells [46]. The expression
pattern of these elements in GTM3 cells was the same as in
normal TM cells. Taken together, the gene expression pattern
of the key proteins involved in actomyosin contraction was
similar to that found in normal TM cells.
MYPT1  phosphorylation  sites  and  their  differential
sensitivity to ROCK inhibitors: Members of the MYPT family
include separate gene products such as MYPT1, MYPT2 (in
striated  muscle  and  brain),  MBS85,  MYPT3,  and  TIMAP
[12]. MYPT1 is expressed in multiple isoforms generated by
alternative splicing showing differential sensitivity to cGMP/
PKG [47]. The doublet of MYPT1, as seen in Figure 2A, is
suggestive of the splice variants of 130 kDa and 133 kDa
[25]. The shorter splice variant in chicken gizzard was shown
to lack a central 123-nucleotide exon and therefore to be
irresponsive  to  Ca2+  sensitization  [48].  Several  sites  on
MYPT1, susceptible to Ser/Thr phosphorylation, regulate the
activity of PP1cδ, leading to the inhibition of MLCP [13]. As
noted earlier, Thr696 and Thr853 of MYPT1 are known sites
phosphorylated  by  ROCK,  which  elicit  enhanced  MLC
phosphorylation through the inhibition of MLCP [14] (also
see Figure 9). In a recent study, it was shown that the substrate
site of PP1cδ, bound to the ankyrin repeat of MYPT1, is
accessible  when  Thr696  and/or  Thr853  are  not
phosphorylated. When phosphorylated, the residues interact
with the active site of PP1cδ and suppress its phosphatase
activity, leading to increased MLC phosphorylation [49].
Employing  site-specific  phospho  antibodies,  we
examined the relative phosphorylation at Thr696 and Thr853
without  and  with  ROCK  inhibitors.  As  expected,  both
Y-27632 and Y-39983 reduced the phosphorylation at Thr696
and Thr853 and led to decreased MLC phosphorylation as
well as reduced actomyosin contraction. It is evident from the
Figure 7. Effect of ROCK inhibition on
cell  morphology  and  focal  adhesions.
Cells grown on coverslips were treated
with 5 μM Y-27632 and 1 μM Y-39983
for  1  h  in  serum-rich  medium  and
stained  for  paxillin  and  F-actin.  DIC
images of these cells were also taken.
A: The DIC image of untreated cells,
which are spread out and have a flat
appearance. B and C: Treatment with
Y-27632 (5 μM) and Y-39983 (1 μM)
for 1 h led to an apparent shrinkage and
retraction of the cells, which assumed a
stellate  appearance.  D:  In  untreated
cells, prominent stress fibers are visible.
Paxillin is seen as large spots within and
at the cell boundaries (G). Treatment
with Y-27632 (E and H) and Y-39983
(F and I) led to a complete loss of stress
fibers and focal adhesions.
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1885IC50  values  summarized  in  Table  2  that  inhibition  of
phosphorylation  at  Thr853  by  both  the  inhibitors  is
pronounced compared with that at Thr696. Moreover, the
IC50 values for dephosphorylation of MLC were close to the
IC50 values for dephosphorylation of MYPT1 at Thr853. This
implies that PP1cδ activity, in other words, activity of MLCP,
is most sensitive to the phosphorylation status of Thr853. In
addition  to  differential  sensitivity  toward  the  site  of
phosphorylation, our data also demonstrates that Y-39983 is
more potent compared with Y-27632. This is apparent in the
IC50  values  obtained  for  dephosphorylation  at  Thr853,
Thr696, and pMLC and is consistent with a previous report
that showed that Y-39983 is 30-fold more potent (IC50 of
Y-39983 and Y-27632 for inhibiting ROCK was 3.6 nM and
110  nM,  respectively)  and  specific  at  inhibiting  ROCK
compared to Y-27632 [19]. Further, at 5 μM concentration,
Y-39983 led to a 100% decrease in the contraction of the
collagen gels while at 10 μM concentration, Y-27632 led to
only a 50% relaxation of the collagen gels (Figure 5). This
observation is consistent with the results obtained with normal
HTM cells wherein 10 μM of Y-27632 allowed only 30% gel
contraction [23]. Finally, Y-39983 has been shown to lead to
a 10-fold decrease in IOP compared to Y-27632 in rabbits
[19].
In addition to MYPT1 phosphorylation and inactivation,
ROCK has been shown to directly phosphorylate recombinant
MLC at Ser19 similar to MLCK [50]. However, this effect has
not been demonstrated in vivo. On the contrary, it has been
shown that the inactivation of the phosphatase activity is more
important for Ca2+ sensitization [51]. Our data also agree with
Figure 8. Influence of ROCK inhibition
on  phosphorylation  of  FAK  and
Paxillin. A: The addition of 10% serum
to  serum-starved  cells  led  to  a
significant  increase  in  the  tyrosine
phosphorylation  of  FAK  tyrosine  at
residue  Tyr397  (middle  lane).  This
increase was opposed by pretreatment
with  Y-39983  (1  μM;  last  lane).  B:
Similarly,  the  serum-induced
phosphorylation of paxillin at Tyr118
(middle  lane)  was  also  opposed  by
Y-39983 (last lane).
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1886the  later  observation  in  that  the  IC50  values  of  MLC
phosphorylation closely follow the IC50 values obtained for
phosphorylation  at  Thr853.  If  there  were  direct
phosphorylation of MLC by ROCK, we would not expect to
see this agreement in the IC50 values.
Effect of ROCK inhibitors on cell-matrix adhesion and
morphology:  A  recent  study  on  TM  demonstrated  that
expression of constitutively active RhoA led to an increase in
stress fibers, actomyosin contraction, focal adhesions, and the
gene expression of various ECM proteins [52]. In the current
study,  relaxation  caused  by  the  inhibition  of  ROCK  is
characterized by retraction of the cells as a result of decreased
cell-ECM interactions.
In  the  past,  cell-ECM  interactions  have  been  studied
using qualitative immunocytochemical techniques. Here, we
have employed a sensitive technique, ECIS, to measure cell-
ECM interactions. This technique has been previously used to
study cell signaling mechanisms by monitoring the changes
in cellular characteristics such as migration [53], cell-cell
adhesions  [30,32],  and  cell-ECM  adhesions  [33,54],  and
morphology [44,55,56]. As observed in this study, the initial
attachment  and  spreading  characteristics  of  the  TM  cells
suggest  that  the  majority  of  resistance  to  current  flow  is
provided by the cell-ECM interactions as opposed to the cell-
cell interactions. This observation is contrary to the findings
in many epithelial and endothelial cells with typical tight
Figure 9. Cell signaling underlying the
regulation  of  actomyosin  contraction.
A: MLC phosphorylation: MLC kinase
(MLCK)  drives  phosphorylation  and
MLC  phosphatase  (MLCP)  induces
dephosphorylation. MLCP is a trimeric
complex  consisting  of  a  phosphatase
(PP1cδ),  a  myosin-binding  subunit
(MYPT1), and a subunit of unknown
function  (M20).  MLCP  activity  is
regulated  by  kinases  like  ROCK  and
integrin-linked  kinase  (ILK)  through
phosphorylation of MYPT1 at specific
sites.  This  inactivates  the  catalytic
subunit,  thus  preventing  MLC
dephosphorylation.  B:  Autoinhibition
of MLCP: The substrate site of PP1cδ is
accessible  when  neither  Thr696  nor
Thr853  is  phosphorylated.  However,
when  MYPT1  is  phosphorylated  at
Thr696 or Thr853, the phosphorylated
residues interact with the active site of
PP1cδ  and  suppress  the  phosphatase
activity. While both ROCK and ILK are
known  to  phosphorylate  Thr696,
phosphorylation at Thr853 seems to be
regulated exclusively by ROCK.
TABLE 2. IC50 FOR INHIBITION OF PHOSPHORYLATION AT THR853 AND THR696 OF MYPT1 BY THE RHO KINASE INHIBITORS.
Target/Function Y-27632 (nM) Y-39983 (nM)
Thr853 658 15
Thr696 2270 177
MLC 1065 14
Relaxation ++ +++++
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1887junctions where the major resistance to current flow lies at the
level of cell-cell junctions [57]. As shown in Figure 6, the
inhibition of ROCK led to a significant decrease in the cell-
substrate  resistance  indicating  a  change  in  cell-matrix
adhesion. Similarly, the resistance obtained with an integrin-
binding  peptide  and  an  actin-depolymerizing  agent  was
decreased compared with untreated cells. These findings are
corroborated by the immunofluorescence data, which show
that treatment with the ROCK inhibitors and the peptide result
in a loss in stress fibers and in the staining for the focal
adhesion proteins paxillin. Finally, serum-induced tyrosine
phosphorylation  of  the  focal  adhesion  proteins,  FAK  and
paxillin,  was  reduced  to  control  levels  by  the  ROCK
inhibitors. These results confirm the reciprocal relationship
between  the  actin  cytoskeleton  and  focal  adhesions  and
support the results reported by a recent publication wherein
treatment with ROCK inhibitors was shown to reduce the
impedance values of GTM cells [58]. However, the extent to
which the change in electric resistance shown in Figure 6 is
convolved with changes in morphology (Figure 7) is yet to be
resolved.
The resistance to outflow facility through the TM is due
to increased actomyosin contraction and/or alterations in the
ECM. These factors are not mutually exclusive, but modulate
each  other.  As  discussed  above,  increased  actomyosin
contraction reduces the outflow facility. This is thought to lead
to the compaction of the TM tissue, which leads to reduced
intertrabecular  pores  and  therefore  an  increase  in  the
resistance to the flow of fluid. On the other hand, the increase
in the deposition of ECM in the anterior chamber can in itself
reduce TM porosity and obstruct the fluid flow. In addition,
the change in the shape of the cells (retraction of cells as seen
with  agents  that  increase  cAMP  and  disrupt  actin
polymerization  and  ROCK  inhibitors)  might  increase  the
porosity of the TM and thus aid the egress of aqueous humor
from the anterior chamber, leading to a reduction in IOP.
Therefore,  it  is  hoped  that,  along  with  the  existing
pharmaceutical  strategies  to  treat  ocular  hypertension,
suitable ROCK inhibitors with adequate efficacy may soon
become available to treat ocular hypertension and glaucoma.
In a recent study [44], we have demonstrated that elevated
intracellular cAMP opposes MLC phosphorylation and leads
to  loss  of  actomyosin  contraction  by  reducing  the
phosphorylation of MYPT1 at Thr853 similar to Rho kinase
inhibitors.  We  also  observed  by  electric  cell  substrate
impedance  measurements  that  by  relaxing  actomyosin
contractility, cAMP opposes cell-matrix adhesion in manner
similar to Rho kinase inhibitors.
In  light  of  suitable  drug  development,  this  study
highlights an important signaling mechanism through which
ROCK inhibits the phosphatase activity, leading to increased
actomyosin contraction. Specifically, the results highlight the
difference in the sensitivities of the two phosphorylation sites
on MYPT1 to ROCK inhibition with the phosphorylation at
Thr853 regulating the phosphorylation of MLC (summarized
in Figure 9). Our ability to establish that Y-39983 is more
potent than Y-27632 at inhibiting phosphatase activity based
on the phosphorylation status of Thr853 suggests that this can
be used as a reliable substrate for establishing the potency of
ROCK inhibitors. With the availability of high throughput
western blot analysis systems [59], and cellular impedance
measurements  [58],  this  knowledge  can  be  used  in  the
screening for potential ROCK inhibitors.
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